| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 03/03/2004 | EP1392862A2 Nucleic acids of the human abca12 gene, vectors containing such nucleic acids, and uses thereof |
| 03/03/2004 | EP1392845A2 A g-protein coupled receptor and uses therefor |
| 03/03/2004 | EP1392838A1 Pseudotyping vih-1 vectors with the aid of rhabdovirus envelopes |
| 03/03/2004 | EP1392837A2 Gene delivery via a baculovirus vector |
| 03/03/2004 | EP1392829A2 Compositions and methods relating to lung specific genes and proteins |
| 03/03/2004 | EP1392827A2 Destruction of prions using vibriolysin or variants thereof |
| 03/03/2004 | EP1392730A2 Transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent |
| 03/03/2004 | EP1392724A2 G-protein coupled receptor |
| 03/03/2004 | EP1392723A2 Medane genes and proteins |
| 03/03/2004 | EP1392366A1 Nuclear receptor-mediated introduction of a pna into cell nuclei |
| 03/03/2004 | EP1392365A2 Compositions and therapeutical use of polynucleotides encoding tcrs |
| 03/03/2004 | EP1392361A1 Anti-cd26 monoclonal antibodies as therapy for diseases associated with cells expressing cd26 |
| 03/03/2004 | EP1392357A2 Vaccine composition |
| 03/03/2004 | EP1392354A2 Use of alpha-1 antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds |
| 03/03/2004 | EP1392351A2 Chemokines as adjuvants of immune response |
| 03/03/2004 | EP1392349A1 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions |
| 03/03/2004 | EP1392345A2 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
| 03/03/2004 | EP1392341A2 Pharmaceutical composition containing a stabilised mrna which is optimised for translation in the coding regions thereof |
| 03/03/2004 | EP1392340A2 Cytotoxic peptides and peptidomimetics based thereon, and methods for use thereof |
| 03/03/2004 | EP1392333A2 Manipulation of arterial-venous identity |
| 03/03/2004 | EP1392272A1 Permeation enhancers |
| 03/03/2004 | EP1392254A1 Micellar drug delivery systems for hydrophobic drugs |
| 03/03/2004 | EP1149167B1 Viral vaccine |
| 03/03/2004 | EP1140020B1 Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles |
| 03/03/2004 | EP1109571B1 Methods of treating salt-dependent hypertension |
| 03/03/2004 | EP1062224A4 Modified factor viii |
| 03/03/2004 | EP1015017B1 Implantable system with drug-eluting cells for on-demand local drug delivery |
| 03/03/2004 | EP0938341B1 Compositions and methods for altering the biodistribution of biological agents |
| 03/03/2004 | EP0871459B1 Vector and method of use for nucleic acid delivery to non-dividing cells |
| 03/03/2004 | EP0859628B9 Drug, in particular for modulating the immunological response for the control of viruses, tumours, bacteria and parasites |
| 03/03/2004 | EP0733103B1 Generation of high titers of recombinant aav vectors |
| 03/03/2004 | EP0636028B1 Self-assembling polynucleotide delivery system comprising an amphiphatic cationic peptide |
| 03/03/2004 | CN1479871A Diagnostic and theraputic methods based on L1 adhesion molecule for ovarian and endometrial tumors |
| 03/03/2004 | CN1479638A Improvement of graft acceptance through manipulation of thymic regeneration |
| 03/03/2004 | CN1479632A Complexes for transferring necleic acids into cells |
| 03/03/2004 | CN1478898A Universal antibody target toward non-virus type lead-in system |
| 03/03/2004 | CN1478541A Design of high effect blood vessel production inhibitor and its application |
| 03/03/2004 | CN1140626C Recombination I-type herpes simplex virus and its application |
| 03/02/2004 | US6701327 Merging network data sets comprising data acquired by interrogation of a network |
| 03/02/2004 | US6699967 Used to treat, prevent, or delay a tissue proliferation-associated disorder |
| 03/02/2004 | US6699965 Used for as a drug screening target; protein from rat and human brains |
| 03/02/2004 | US6699838 Antiangiogenic peptides |
| 03/02/2004 | US6699690 Linked and controlling the expression of a heterologous enzyme, for example varicella zoster virus thymidine kinase or non-mammaliam cytosine deaminase |
| 03/02/2004 | US6699686 Modified nuclear glucocorticoid receptor, fusion protein, and DNA fragments coding for said receptor and said fusion protein |
| 03/02/2004 | US6699683 Active site of human gamma glutamy hydrolase |
| 03/02/2004 | US6699660 Isolated nucleic acid identical to one expressed in response to seizure or ischemia |
| 03/02/2004 | US6699476 Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules |
| 03/02/2004 | US6699468 Defective expression of the gamma 34.5 gene and the ribonucleotide reductase gene |
| 02/26/2004 | WO2004016805A2 Immunostimulatory nucleic acids |
| 02/26/2004 | WO2004016803A2 Method of enhancing cd4+ t cell responses |
| 02/26/2004 | WO2004016787A1 Modified tailed oligonucleotides |
| 02/26/2004 | WO2004016764A2 eNOS MUTANTS USEFUL FOR GENE THERAPY |
| 02/26/2004 | WO2004016761A2 Gene therapy for critical limb ischemia with wild type or mutant enos |
| 02/26/2004 | WO2004016731A2 Ex-vivo expansion of hematopoietic stem cell populations in mononuclear cell cultures |
| 02/26/2004 | WO2004016726A2 Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms |
| 02/26/2004 | WO2004016639A1 Bmp-2 estrogen responsive element and methods of using the same |
| 02/26/2004 | WO2004016638A1 Aptamer-mediated regulation of gene expression |
| 02/26/2004 | WO2004016283A2 Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use |
| 02/26/2004 | WO2004016215A2 Use of antisense oligonucleotides to inhibit the expression of akt-1 |
| 02/26/2004 | WO2004016151A2 Pthrp-derived modulators of smooth muscle proliferation |
| 02/26/2004 | WO2004005341A3 Full-length interferon gamma polypeptide variants |
| 02/26/2004 | WO2004004763A3 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 02/26/2004 | WO2004000881A9 Dna sequence and recombinant production of the grass pollen allergen phl p4 |
| 02/26/2004 | WO2003098223A3 A method for killing cells by inhibiting histone activity in the cell |
| 02/26/2004 | WO2003095652A3 Expression constructs for producing double-stranded (ds) rna and the use thereof |
| 02/26/2004 | WO2003094862A3 tRNA SYNTHASE: MODULATORS OF ANGIOGENESIS |
| 02/26/2004 | WO2003091387A9 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 02/26/2004 | WO2003089618A3 Transposon system and methods of use |
| 02/26/2004 | WO2003089590A3 TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH |
| 02/26/2004 | WO2003087841A3 An ephrin-b receptor protein involved in carcinoma |
| 02/26/2004 | WO2003087345A3 Stimulation of nerve cell regeneration |
| 02/26/2004 | WO2003083117A3 Vascularization controlling gene |
| 02/26/2004 | WO2003083050A3 Human deubiquitinating protease gene on chromosome 7 and its murine ortholog |
| 02/26/2004 | WO2003083037A3 Minimizing metal toxicity during electroporation enhanced delivery of polynucleotides |
| 02/26/2004 | WO2003073998A3 Local production and/or delivery of anti-cancer agents by stromal cell precursors |
| 02/26/2004 | WO2003066813A3 MINRs AS MODIFIERS OF INSULIN RECEPTOR SIGNALING AND METHODS OF USE |
| 02/26/2004 | WO2003057892A3 Viruses with enhanced lytic potency |
| 02/26/2004 | WO2003057846A3 Methods and materials for modulating task-3 |
| 02/26/2004 | WO2003057829A3 Methods of generating multispecific, multivalent agents from vh and vl domains |
| 02/26/2004 | WO2003054019A3 Therapeutic monoclonal anti-tirc7 antibodies for use in immune related and other diseases |
| 02/26/2004 | WO2003040346A3 Methods and compositions for the use of stromal cells to support embryonic and adult stem cells |
| 02/26/2004 | WO2003040325A3 Novel proteins and nucleic acids encoding same |
| 02/26/2004 | WO2003039476A3 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 |
| 02/26/2004 | WO2003038058A3 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| 02/26/2004 | WO2003030719A3 Methods and kits for use in selecting approaches to treating cancer |
| 02/26/2004 | WO2003029412A3 Restricted expression lentivial vectors |
| 02/26/2004 | WO2003028543A3 Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease |
| 02/26/2004 | WO2003022212A3 Anti-tumor effects of prostate carcinoma tumor antigen-1 |
| 02/26/2004 | WO2003015708A3 Composition and method for treating hiv infection |
| 02/26/2004 | WO2003010320A3 Recombinant vector derived from adeno-associated virus for gene therapy |
| 02/26/2004 | WO2002103014A3 Antisense oligonucleotides which can inhibit the formation of capillary tubes by endothelial cells |
| 02/26/2004 | WO2002102973A3 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 02/26/2004 | WO2002099047A3 PROMLs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 02/26/2004 | WO2002098424B1 Novel anti-infectives |
| 02/26/2004 | WO2002087419A3 Biological pacemaker |
| 02/26/2004 | WO2002083917A8 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer |
| 02/26/2004 | WO2002074808A3 Modified insulin with reduced immunogenicity |
| 02/26/2004 | WO2002062204A3 Methods for diagnosing and treating heart disease |
| 02/26/2004 | WO2002051237A3 Helicobacter proteins, nucleic acids and uses thereof |
| 02/26/2004 | WO2002038775A3 METHODS FOR PRODUCING AND PURIFYING RECOMBINANT α-L-IDURONIDASE |